Novel Antibodies against a Ground-Breaking New Target for the Treatment of Cardiovascular Fibrosis Developed by Enleofen Bio,...
14 November 2017 - 8:00PM
Business Wire
Abzena plc (AIM: ABZA, ‘Abzena’), the life sciences group
providing services and technologies to enable the development and
manufacture of biopharmaceutical products, works with Enleofen Bio
Pte Ltd (‘Enleofen Bio'), to develop first-in-class antibody
therapeutics for the treatment of fibrotic human diseases.
The Founders of Enleofen Bio discovered that inhibiting
Interleukin 11 (IL11) prevents fibrosis through a wide range of
pathways, putting it at the very centre of the fibrotic process.
This breakthrough research was published today in Nature, the
leading scientific journal.
Enleofen Bio has developed a wide range of potent IL11
inhibitors and its fully human antibody development program is
being advanced with the use of Abzena’s Composite CHO™ cell line
technology. Enleofen Bio may in the future opt to progress with
large scale manufacturing at Abzena’s San Diego facility.
Abzena will also support Enleofen Bio through the development of
alternative strategies to block IL11 signalling. Abzena’s wide
range of protein engineering technologies will help to translate
findings from successful proof-of-concept studies in preclinical
models of disease to the clinic.
Enleofen is currently investing proceeds from a successful
Series A fundraising into the development of novel fibrosis
treatments. Enleofen has an exclusive licence to a comprehensive
suite of patent applications covering IL11’s role in fibrosis and a
range of products to treat fibrosis.
Prof Stuart Cook, co-founder of Enleofen
Bio, commented:
“IL11 is a truly outstanding drug target for preventing
fibrosis. Organ fibrosis causes deaths of millions of people around
the world and current treatment options are very limited. We
believe anti-IL11 therapies will transform the treatment of
patients suffering from fibrosis of the lung, heart, liver, kidneys
and other organs”
“We chose to work with Abzena because of its proven expertise in
antibody engineering and cell line development.”
Campbell Bunce, SVP Scientific Operations, said:
“We believe our expertise and integrated offering across biology
and biomanufacturing will allow Enleofen Bio seamless development
across its portfolio of novel treatments for preventing fibrosis
.
“This agreement represents another example of customers using a
range of Abzena’s services to enable their biopharmaceutical
development program.”
-Ends-
Notes to Editors
For the full release, including further information on Enleofen
Bio and Fibrosis, please visit Abzena’s website:
http://www.abzena.com/media/news/
Publication in Nature
This study was published online on 13 November 2017, time, in
Nature, under the title “IL11 is a crucial determinant of
cardiovascular fibrosis” by Sebastian Schafer et al.
About Abzena PLC
Abzena (AIM: ABZA) provides proprietary technologies and
complementary services to enable the development and manufacture of
biopharmaceutical products. The term ‘Abzena Inside’ is used by
Abzena to describe products that have been created using its
proprietary technologies and are being developed by its partners,
and include Composite Human Antibodies™ and ThioBridge™ Antibody
Drug Conjugates (ADCs). Abzena has the potential to earn future
licence fees, milestone payments and/or royalties on ‘Abzena
Inside’ products.
Abzena offers the following services and technologies across its
principal sites in Cambridge (UK), San Diego, California (USA) and
Bristol, Pennsylvania (USA):
- Immunology research studies, including
immunogenicity assessment of candidate biopharmaceutical
products;
- Protein engineering to create humanized
antibodies and deimmunised therapeutic proteins;
- Cell line development for the
manufacture of recombinant proteins and antibodies;
- Contract process development and GMP
manufacture of biopharmaceuticals, including monoclonal antibodies
and recombinant proteins for preclinical and clinical studies;
- Contract synthetic chemistry and
bioconjugation research services, focused on antibody-drug
conjugates (ADCs); and
- Proprietary site-specific conjugation
technologies and novel payloads for ADC development; and GMP
manufacturer of ADC linkers, payloads & combined
linker-payloads.
For more information, please see www.abzena.com
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171114005718/en/
Abzena PLCJohn Burt, CEO+44 1223 903498orCampbell Bunce,
SVP Scientific OperationsMin Park, Global Head of Marketing+1 267
54 7752orInstinctif Partners (Abzena)Melanie Toyne Sewell /
Alex Shaw / Deborah Bell+44 20 7457
2020abzena@instinctif.comorEnleofen Bio Pte LtdStuart Cook,
Co-Founderinfo@enleofen.com
Abzena (LSE:ABZA)
Historical Stock Chart
From Apr 2024 to May 2024
Abzena (LSE:ABZA)
Historical Stock Chart
From May 2023 to May 2024